CS-807 IN THE SURGICAL FIELD

概要

論文の詳細を見る
Basic and clinical studies on CS-807, a new oral cephalosporin, were investigated and the following results were obtained. Antibacterial activities of CS-807 against clinical isolates were compared with those of ampicillin (ABPC), amoxicillin (AMPC), flucloxacillin (MFIPC), cephalexin (CEX), cefaclor (CCL), norfloxacin (NFLX), ofloxacion (OFLX) and minocycline (MINO). MICs of CS-807 were studied against clinical isolates such as coagulase positive Staphylococci, negative Staphylococci, E. faecalis, E. coli, K. pneumoniae and E. cloacae, CS-807 showed almost equal activity to AMPC against Staphylococci, but showed less activity against E. faecalis. It also demonstrated good activity against E. coli and excellent against K. pneumoniae. In 5 patients given 200mg of CS-807, the serum levels were 2.45-3.55μg/ml at 4 hours after administration in 3 cases. In 2 cases serum levels were 1.19-1.95μg/ml at 6 hours after administration. The bile levels were lower than those of serum without one case. In the clinical study, CS-807 was administered to 26 patients consisting mainly of skin and soft tissue infections. Clinical responses were good enough in 23 cases (88.4%) and poor in 3 cases. No serious side effects were noted.
公益社団法人日本化学療法学会の論文